Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Dalle, JH; Auvrignon, A; Vassal, G; Leverger, G; Kalifa, C
   Interaction between methotrexate and ciprofloxacin: report of two cases ofsevere intoxication
   ARCHIVES DE PEDIATRIE
   
   J.H. Dalle et al., "Interaction between methotrexate and ciprofloxacin: report of two cases ofsevere intoxication", ARCH PED, 8(10), 2001, pp. 1078-1081
2. Vassal, G; Tranchand, B; Valteau-Couanet, D; Mahe, C; Couanet, D; Schoeppfer, C; Grill, J; Kalifa, C; Hill, C; Ardiet, C; Hartmann, O
   Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
   BONE MARROW TRANSPLANTATION
   
   G. Vassal et al., "Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma", BONE MAR TR, 27(5), 2001, pp. 471-477
3. Baudin, E; Pellegriti, G; Bonnay, M; Penfornis, A; Laplanche, A; Vassal, G; Schlumberger, M
   Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p ' DDD)levels on the treatment of patients with adrenocortical carcinoma
   CANCER
   
   E. Baudin et al., "Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p ' DDD)levels on the treatment of patients with adrenocortical carcinoma", CANCER, 92(6), 2001, pp. 1385-1392
4. Doz, F; Gentet, JC; Pein, F; Frappaz, D; Chastagner, P; Moretti, S; Vassal, G; Arditti, J; Van Tellingen, O; Illiadis, A; Catalin, J
   Phase I trial and pharmacological study of a 3-hour paclitaxel infusion inchildren with refractory solid tumours: a SFOP study
   BRITISH JOURNAL OF CANCER
   
   F. Doz et al., "Phase I trial and pharmacological study of a 3-hour paclitaxel infusion inchildren with refractory solid tumours: a SFOP study", BR J CANC, 84(5), 2001, pp. 604-610
5. Chastagner, P; Merlin, JL; Marchal, C; Hoffstetter, S; Barberi-Heyob, M; Vassal, G; Duprez, A
   In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice
   CLINICAL CANCER RESEARCH
   
   P. Chastagner et al., "In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice", CLIN CANC R, 6(8), 2000, pp. 3327-3333
6. Santos, A; Zanetta, S; Cresteil, T; Deroussent, A; Pein, F; Raymond, E; Vernillet, L; Risse, ML; Boige, V; Gouyette, A; Vassal, G
   Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
   CLINICAL CANCER RESEARCH
   
   A. Santos et al., "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans", CLIN CANC R, 6(5), 2000, pp. 2012-2020
7. Oberlin, O; Brugieres, L; Patte, C; Kalifa, C; Vassal, G; Valteau-Couanet, D; Hartmann, O
   Recent progress in pediatric oncology.
   ARCHIVES DE PEDIATRIE
   
   O. Oberlin et al., "Recent progress in pediatric oncology.", ARCH PED, 7(8), 2000, pp. 866-878
8. Valteau-Couanet, D; Benhamou, E; Vassal, G; Stambouli, F; Lapierre, V; Couanet, D; Lumbroso, J; Hartmann, O
   Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
   BONE MARROW TRANSPLANTATION
   
   D. Valteau-Couanet et al., "Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma", BONE MAR TR, 25(9), 2000, pp. 937-942
9. Griscelli, F; Li, H; Cheong, C; Opolon, P; Bennaceur-Griscelli, A; Vassal, G; Soria, J; Soria, C; Lu, H; Perricaudet, M; Yeh, P
   Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model
   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
   
   F. Griscelli et al., "Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model", P NAS US, 97(12), 2000, pp. 6698-6703
10. Logie, A; Boudou, P; Boccon-Gibod, L; Baudin, E; Vassal, G; Schlumberger, M; Le Bouc, Y; Gicquel, C
    Establishment and characterization of a human adrenocortical carcinoma xenograft model
    ENDOCRINOLOGY
    
    A. Logie et al., "Establishment and characterization of a human adrenocortical carcinoma xenograft model", ENDOCRINOL, 141(9), 2000, pp. 3165-3171
11. Badie, C; Bourhis, J; Sobczak-Thepot, J; Haddada, H; Chiron, M; Janicot, M; Janot, F; Tursz, T; Vassal, G
    p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line
    BRITISH JOURNAL OF CANCER
    
    C. Badie et al., "p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line", BR J CANC, 82(3), 2000, pp. 642-650
12. Vassal, G; Pinkerton, CR
    Experimental therapeutics and new agents for neuroblastoma
    NEUROBLASTOMA
    
    G. Vassal e C.R. Pinkerton, "Experimental therapeutics and new agents for neuroblastoma", NEUROBLASTOMA, 2000, pp. 383-392
13. Le Cesne, A; Vassal, G; Farace, F; Spielmann, M; Le Chevalier, T; Angevin, E; Valteau-Couanet, D; Fizazi, K; Cojean, I; Llombard, A; Tursz, T; Escudier, B
    Combination interleukin-2 and doxorubicin in advanced adult solid tumors: Circumvention of doxorubicin resistance in soft-tissue sarcoma?
    JOURNAL OF IMMUNOTHERAPY
    
    A. Le Cesne et al., "Combination interleukin-2 and doxorubicin in advanced adult solid tumors: Circumvention of doxorubicin resistance in soft-tissue sarcoma?", J IMMUNOTH, 22(3), 1999, pp. 268-277
14. Hartmann, O; Valteau-Couanet, D; Vassal, G; Lapierre, V; Brugieres, L; Delgado, R; Couanet, D; Lumbroso, J; Benhamou, E
    Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution
    BONE MARROW TRANSPLANTATION
    
    O. Hartmann et al., "Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution", BONE MAR TR, 23(8), 1999, pp. 789-795
15. Lescop, S; Lellouch-Tubiana, A; Vassal, G; Besnard-Guerin, C
    Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas
    JOURNAL OF NEURO-ONCOLOGY
    
    S. Lescop et al., "Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas", J NEURO-ONC, 44(2), 1999, pp. 119-127
16. Boland, I; Vassal, G; Morizet, J; Terrier-Lacombe, MJ; Valteau-Couanet, D; Kalifa, C; Hartmann, O; Gouyette, A
    Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations
    BRITISH JOURNAL OF CANCER
    
    I. Boland et al., "Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations", BR J CANC, 79(5-6), 1999, pp. 787-792
17. Avet-Loiseau, H; Venuat, AM; Terrier-Lacombe, MJ; Lellouch-Tubiana, A; Zerah, M; Vassal, G
    Comparative genome hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children
    BRITISH JOURNAL OF CANCER
    
    H. Avet-Loiseau et al., "Comparative genome hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children", BR J CANC, 79(11-12), 1999, pp. 1843-1847
18. VASSAL G; BOLAND I; TERRIERLACOMBE MJ; WATSON AJ; MARGISON GP; VENUAT AM; MORIZET J; PARKER F; LACROIX C; LELLOUCHTUBIANA A; PIERREKAHN A; POULLAIN MG; GOUYETTE A
    ACTIVITY OF FOTEMUSTINE IN MEDULLOBLASTOMA AND MALIGNANT GLIOMA XENOGRAFTS IN RELATION TO O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND ALKYLPURINE-DNA N-GLYCOSYLASE ACTIVITY
    Clinical cancer research
    
    G. Vassal et al., "ACTIVITY OF FOTEMUSTINE IN MEDULLOBLASTOMA AND MALIGNANT GLIOMA XENOGRAFTS IN RELATION TO O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND ALKYLPURINE-DNA N-GLYCOSYLASE ACTIVITY", Clinical cancer research, 4(2), 1998, pp. 463-468
19. VASSAL G; BOLAND I; TERRIERLACOMBE MJ; WATSON AJ; MARGISON GP; VENUAT AM; MORIZET J; PARKER F; LACROIX C; LELLOUCHTUBIANA A; PIERREKAHN A; POULLAIN MG; GOUYETTE A
    ACTIVITY OF FOTEMUSTINE IN MEDULLOBLASTOMA AND MALIGNANT GLIOMA XENOGRAFTS IN RELATION TO O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND ALKYLPURINE-DNA N-GLYCOSYLASE ACTIVITY
    Clinical cancer research
    
    G. Vassal et al., "ACTIVITY OF FOTEMUSTINE IN MEDULLOBLASTOMA AND MALIGNANT GLIOMA XENOGRAFTS IN RELATION TO O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND ALKYLPURINE-DNA N-GLYCOSYLASE ACTIVITY", Clinical cancer research, 4(2), 1998, pp. 463-468
20. BOIGE V; RAYMOND E; FABBRO M; PLAZZA J; VASSAL G; RISSE ML; RODIER JM; ARMAND JP
    PHASE-II TRIAL AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) IN PATIENTS WITH GLIOBLASTOMA
    Annals of oncology
    
    V. Boige et al., "PHASE-II TRIAL AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) IN PATIENTS WITH GLIOBLASTOMA", Annals of oncology, 9, 1998, pp. 657-657
21. SALIBA F; HAGIPANTELLI R; MISSET JL; BASTIAN G; VASSAL G; BONNAY M; HERAIT P; COTE C; MAHJOUBI M; MIGNARD D; CVITKOVIC E
    PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT
    Journal of clinical oncology
    
    F. Saliba et al., "PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT", Journal of clinical oncology, 16(8), 1998, pp. 2745-2751
22. SMITH M; BERNSTEIN M; BLEYER WA; BORSI JD; HO P; LEWIS IJ; PEARSON A; PEIN F; PRATT C; REAMAN G; RICCARDI R; SEIBEL N; TRUEWORTHY R; UNGERLEIDER R; VASSAL G; VIETTI T
    CONDUCT OF PHASE-I TRIALS IN CHILDREN WITH CANCER
    Journal of clinical oncology
    
    M. Smith et al., "CONDUCT OF PHASE-I TRIALS IN CHILDREN WITH CANCER", Journal of clinical oncology, 16(3), 1998, pp. 966-978
23. VASSAL G; PONDARRE C; BOLAND I; CAPPELLI C; SANTOS A; THOMAS C; LUCCHI E; IMADALOU K; PEIN F; MORIZET J; GOUYETTE A
    PRECLINICAL DEVELOPMENT OF CAMPTOTHECIN DERIVATIVES AND CLINICAL-TRIALS IN PEDIATRIC ONCOLOGY
    Biochimie
    
    G. Vassal et al., "PRECLINICAL DEVELOPMENT OF CAMPTOTHECIN DERIVATIVES AND CLINICAL-TRIALS IN PEDIATRIC ONCOLOGY", Biochimie, 80(3), 1998, pp. 271-280
24. LEVU B; DEVATHAIRE F; SHAMSALDIN A; HAWKINS MM; GRIMAUD E; HARDIMAN C; DIALLO I; VASSAL G; BESSA E; CAMPBELL S; PANIS X; DALYSCHVEITZER N; LAGRANGE JL; ZUCKER JM; ESCHWEGE F; CHAVAUDRA J; LEMERLE J
    RADIATION-DOSE, CHEMOTHERAPY AND RISK OF OSTEOSARCOMA AFTER SOLID TUMORS DURING CHILDHOOD
    International journal of cancer
    
    B. Levu et al., "RADIATION-DOSE, CHEMOTHERAPY AND RISK OF OSTEOSARCOMA AFTER SOLID TUMORS DURING CHILDHOOD", International journal of cancer, 77(3), 1998, pp. 370-377
25. Vassal, G
    Methodology and limits of preclinical evaluation during the development ofanticancer drug combinations
    BULLETIN DU CANCER
    
    G. Vassal, "Methodology and limits of preclinical evaluation during the development ofanticancer drug combinations", B CANCER, 85(11), 1998, pp. 929-934
26. VASSAL G; PONDARRE C; CAPPELLI C; TERRIERLACOMBE MJ; BOLAND I; MORIZET J; BENARD J; VENUAT AM; ARDOUIN P; HARTMANN O; GOUYETTE A
    DNA-TOPOISOMERASE-I, A NEW TARGET FOR THE TREATMENT OF NEUROBLASTOMA
    European journal of cancer
    
    G. Vassal et al., "DNA-TOPOISOMERASE-I, A NEW TARGET FOR THE TREATMENT OF NEUROBLASTOMA", European journal of cancer, 33(12), 1997, pp. 2011-2015
27. HARTMANN O; VALTEAUCOUANET D; BENHAMOU E; VASSAL G; RUBIE H; BEAUJEAN F; LEMERLE J
    STAGE-IV NEUROBLASTOMA IN PATIENTS OVER 1 YEAR OF AGE AT DIAGNOSIS - CONSOLIDATION OF POOR RESPONDERS WITH COMBINED BUSULFAN, CYCLOPHOSPHAMIDE AND MELPHALAN FOLLOWED BY IN-VITRO MAFOSFAMIDE-PURGED AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    European journal of cancer
    
    O. Hartmann et al., "STAGE-IV NEUROBLASTOMA IN PATIENTS OVER 1 YEAR OF AGE AT DIAGNOSIS - CONSOLIDATION OF POOR RESPONDERS WITH COMBINED BUSULFAN, CYCLOPHOSPHAMIDE AND MELPHALAN FOLLOWED BY IN-VITRO MAFOSFAMIDE-PURGED AUTOLOGOUS BONE-MARROW TRANSPLANTATION", European journal of cancer, 33(12), 1997, pp. 2126-2129
28. PEIN F; DOZ F; FRAPPAZ D; LUCCHI E; MORETTI S; SANTOS D; MIGNARD D; VASSAL G
    PHASE-I TRIAL OF IRINOTECAN (CPT-11)I IN CHILDHOOD SOLID TUMORS
    European journal of cancer
    
    F. Pein et al., "PHASE-I TRIAL OF IRINOTECAN (CPT-11)I IN CHILDHOOD SOLID TUMORS", European journal of cancer, 33, 1997, pp. 1126-1126
29. VASSAL G; BOLAND I; SANTOS A; BISSERY MC; TERRIERLACOMBE MJ; MORIZET J; SAINTEROSE C; LELLOUCHTUBIANA A; KALIFA C; GOUYETTE A
    POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE
    International journal of cancer
    
    G. Vassal et al., "POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE", International journal of cancer, 73(1), 1997, pp. 156-163
30. RAMIREZ LH; ZHAO ZX; ROUGIER P; BOGNEL C; DZODIC R; VASSAL G; ARDOUIN P; GOUYETTE A; MUNCK JN
    PHARMACOKINETICS AND ANTITUMOR EFFECTS OF MITOXANTRONE AFTER INTRATUMORAL OR INTRAARTERIAL HEPATIC ADMINISTRATION IN RABBITS
    Cancer chemotherapy and pharmacology
    
    L.H. Ramirez et al., "PHARMACOKINETICS AND ANTITUMOR EFFECTS OF MITOXANTRONE AFTER INTRATUMORAL OR INTRAARTERIAL HEPATIC ADMINISTRATION IN RABBITS", Cancer chemotherapy and pharmacology, 37(4), 1996, pp. 371-376
31. VASSAL G; KOSCIELNY S; CHALLINE D; VALTEAUCOUANET D; BOLAND I; DEROUSSENT A; LEMERLE J; GOUYETTE A; HARTMANN O
    BUSULFAN DISPOSITION AND HEPATIC VENOOCCLUSIVE DISEASE IN CHILDREN UNDERGOING BONE-MARROW TRANSPLANTATION
    Cancer chemotherapy and pharmacology
    
    G. Vassal et al., "BUSULFAN DISPOSITION AND HEPATIC VENOOCCLUSIVE DISEASE IN CHILDREN UNDERGOING BONE-MARROW TRANSPLANTATION", Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 247-253
32. GRILL J; LEDELEY MC; VALTEAUCOUANET D; VASSAL G; BONNAY M; BENHAMOU E; HARTMANN O
    PREVIOUS CONVENTIONAL CHEMOTHERAPY IS THE PRINCIPAL RISK FACTOR FOR IMMUNOGLOBULIN DEFICIENCY DURING THE EARLY POST-ABMT PERIOD IN CHILDREN
    Bone marrow transplantation
    
    J. Grill et al., "PREVIOUS CONVENTIONAL CHEMOTHERAPY IS THE PRINCIPAL RISK FACTOR FOR IMMUNOGLOBULIN DEFICIENCY DURING THE EARLY POST-ABMT PERIOD IN CHILDREN", Bone marrow transplantation, 18(2), 1996, pp. 325-332
33. VALTEAUCOUANET D; VASSAL G; PONDARRE C; BONNAY M; BENHAMOU E; COUANET D; PLANTAZ D; HARTMANN O
    PHASE-I STUDY OF HIGH-DOSE CONTINUOUS INTRAVENOUS-INFUSION OF VP-16 IN COMBINATION WITH HIGH-DOSE MELPHALAN FOLLOWED BY AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CHILDREN WITH STAGE-IV NEUROBLASTOMA
    Bone marrow transplantation
    
    D. Valteaucouanet et al., "PHASE-I STUDY OF HIGH-DOSE CONTINUOUS INTRAVENOUS-INFUSION OF VP-16 IN COMBINATION WITH HIGH-DOSE MELPHALAN FOLLOWED BY AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CHILDREN WITH STAGE-IV NEUROBLASTOMA", Bone marrow transplantation, 17(4), 1996, pp. 485-489
34. VASSAL G; TERRIERLACOMBE MJ; LELLOUCHTUBIANA A; VALERY CA; SAINTEROSE C; MORIZET J; ARDOUIN P; RIOU G; KALIFA C; GOUYETTE A
    TUMORIGENICITY OF CEREBELLAR PRIMITIVE NEURO-ECTODERMAL TUMORS IN ATHYMIC MICE CORRELATES WITH POOR-PROGNOSIS IN CHILDREN
    International journal of cancer
    
    G. Vassal et al., "TUMORIGENICITY OF CEREBELLAR PRIMITIVE NEURO-ECTODERMAL TUMORS IN ATHYMIC MICE CORRELATES WITH POOR-PROGNOSIS IN CHILDREN", International journal of cancer, 69(2), 1996, pp. 146-151
35. VASSAL G; TERRIERLACOMBE MJ; BISSERY MC; VENUAT AM; GYERGYAY F; BENARD J; MORIZET J; BOLAND I; ARDOUIN P; BRESSACDEPAILLERETS B; GOUYETTE A
    THERAPEUTIC ACTIVITY OF CPT-11, A DNA-TOPOISOMERASE-I INHIBITOR, AGAINST PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR AND NEUROBLASTOMA XENOGRAFTS
    British Journal of Cancer
    
    G. Vassal et al., "THERAPEUTIC ACTIVITY OF CPT-11, A DNA-TOPOISOMERASE-I INHIBITOR, AGAINST PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR AND NEUROBLASTOMA XENOGRAFTS", British Journal of Cancer, 74(4), 1996, pp. 537-545
36. DANGLOT G; REGNIER V; FAUVET D; VASSAL G; KUJAS M; BERNHEIM A
    NEUROFIBROMATOSIS-1 (NF1) MESSENGER-RNAS EXPRESSED IN THE CENTRAL-NERVOUS-SYSTEM ARE DIFFERENTIALLY SPLICED IN THE 5' PART OF THE GENE
    Human molecular genetics
    
    G. Danglot et al., "NEUROFIBROMATOSIS-1 (NF1) MESSENGER-RNAS EXPRESSED IN THE CENTRAL-NERVOUS-SYSTEM ARE DIFFERENTIALLY SPLICED IN THE 5' PART OF THE GENE", Human molecular genetics, 4(5), 1995, pp. 915-920
37. LECESNE A; VASSAL G; FARACE F; SPIELMANN M; LECHEVALIER T; TURSZ T; ESCUDIER B
    CONCOMITANT INTERLEUKIN-2-DOXORUBICIN (ADR) SCHEDULE IN PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) - A PHARMACOKINETIC STUDY
    European journal of cancer
    
    A. Lecesne et al., "CONCOMITANT INTERLEUKIN-2-DOXORUBICIN (ADR) SCHEDULE IN PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) - A PHARMACOKINETIC STUDY", European journal of cancer, 31A, 1995, pp. 586-586
38. MISSET JL; SALIBA F; GIACCHETTI S; BRAIN E; VASSAL G; BONNAY M; BASTIAN G; COTE C; MAHJOUBI M; HERAIT P; HAGIPANTELLI R; CVITKOVIC E
    PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT
    European journal of cancer
    
    J.L. Misset et al., "PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT", European journal of cancer, 31A, 1995, pp. 742-742
39. PEIN F; VASSAL G; SAKIROGLU C; TOURNADE MF; LEMERLE J
    PEDIATRIC FEATURES OF ANTHRACYCLINES CARD IAC TOXICITY AND PRACTICAL IMPLICATIONS FOR PREVENTION
    Archives de pediatrie
    
    F. Pein et al., "PEDIATRIC FEATURES OF ANTHRACYCLINES CARD IAC TOXICITY AND PRACTICAL IMPLICATIONS FOR PREVENTION", Archives de pediatrie, 2(10), 1995, pp. 988-999
40. VASSAL G; PEIN F
    LONG-TERM RISK-FACTORS OF ANTICANCER MEDI CATION FOR CHILDREN
    Archives de pediatrie
    
    G. Vassal e F. Pein, "LONG-TERM RISK-FACTORS OF ANTICANCER MEDI CATION FOR CHILDREN", Archives de pediatrie, 2, 1995, pp. 104-105
41. CANIONI D; VASSAL G; DONADIEU J; HUBERT P; BROUSSE N
    TOXICITY INDUCED BY CHEMOTHERAPY MIMICKING CYTOMEGALOVIRUS GASTRITIS
    Histopathology
    
    D. Canioni et al., "TOXICITY INDUCED BY CHEMOTHERAPY MIMICKING CYTOMEGALOVIRUS GASTRITIS", Histopathology, 26(5), 1995, pp. 473-475
42. AUTRET E; VASMANT D; BEGAUD B; DUPORTAL HD; BOUTROY MJ; CEZARD JP; DELBOS L; ESCHWEGE E; GOUJARD J; ICHOU F; JACQZAIGRAIN E; KOUZAN S; LASSALE C; LEROY B; OSTINELLI J; PLETAN Y; PONS G; SAUVANET JP; SINGLAS E; TABURET AM; THERENEFENOGLIO MC; TILLEMENT JP; VASSAL G; SAINTSALVY B
    DETERMINATION OF DRUG-DOSAGE IN PEDIATRIC S
    Therapie
    
    E. Autret et al., "DETERMINATION OF DRUG-DOSAGE IN PEDIATRIC S", Therapie, 50(4), 1995, pp. 381-386
43. VASSAL G
    PHARMACOLOGICALLY-GUIDED DOSE ADJUSTMENT OF BUSULFAN IN HIGH-DOSE CHEMOTHERAPY REGIMENS - RATIONALE AND PITFALLS
    Anticancer research
    
    G. Vassal, "PHARMACOLOGICALLY-GUIDED DOSE ADJUSTMENT OF BUSULFAN IN HIGH-DOSE CHEMOTHERAPY REGIMENS - RATIONALE AND PITFALLS", Anticancer research, 14(6A), 1994, pp. 2363-2370
44. VASSAL G; PEIN F; GOUYETTE A; LEMERLE J
    DEVELOPMENT OF NEW ANTICANCER AGENTS IN C HILDREN - METHODOLOGY, DIFFICULTIES, AND STRATEGIES
    Annales de pediatrie
    
    G. Vassal et al., "DEVELOPMENT OF NEW ANTICANCER AGENTS IN C HILDREN - METHODOLOGY, DIFFICULTIES, AND STRATEGIES", Annales de pediatrie, 41(8), 1994, pp. 477-484
45. VASSAL G
    THERAPEUTIC DEVELOPMENT AND CLINICAL-PHAR MACOLOGY IN PEDIATRIC ONCOLOGY
    Annales de pediatrie
    
    G. Vassal, "THERAPEUTIC DEVELOPMENT AND CLINICAL-PHAR MACOLOGY IN PEDIATRIC ONCOLOGY", Annales de pediatrie, 41(8), 1994, pp. 502-509
46. VASSAL G; BOLAND I; DEROUSSENT A; GEORGIN D; NOEL JP; GOUYETTE A
    IN-VITRO BUSULFAN METABOLISM IN HUMAN AND MOUSE-LIVER
    Bulletin du cancer
    
    G. Vassal et al., "IN-VITRO BUSULFAN METABOLISM IN HUMAN AND MOUSE-LIVER", Bulletin du cancer, 81(11), 1994, pp. 946-946
47. VASSAL G; FISCHER A; CHALLINE D; BOLAND I; LEDHEIST F; LEMERLE S; VILMER E; RAHIMY C; SOUILLET G; GLUCKMAN E; MICHEL G; DEROUSSENT A; GOUYETTE A
    BUSULFAN DISPOSITION BELOW THE AGE OF 3 - ALTERATION IN CHILDREN WITHLYSOSOMAL STORAGE DISEASE
    Blood
    
    G. Vassal et al., "BUSULFAN DISPOSITION BELOW THE AGE OF 3 - ALTERATION IN CHILDREN WITHLYSOSOMAL STORAGE DISEASE", Blood, 82(3), 1993, pp. 1030-1034